Skip to Main Content

Paper Details

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Neuro Oncol
44
2023
IDH, Isocitrate, Isocitrate dehydrogenase, Isocitrate dehydrogenase (IDH) mutant gliomas, malignant, patients, primary brain tumors, tumors
Author NameAffiliation
Michael WellerUniversity Hospital Zurich
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program
Timothy F Cloughesyuniversity of california los angeles Neuro-Oncology Program
Jill S Barnholtz-SloanCenter for Biomedical Informatics and Information Technology (CBIIT), National Cancer Institute (NCI)
Jill S Barnholtz-SloanCenter for Biomedical Informatics and Information Technology (CBIIT), National Cancer Institute (NCI)
Mitchel S BergerUniversity of California-San Francisco
Mitchel S BergerUniversity of California-San Francisco
Wenya Linda BiHarvard Medical School
Wenya Linda BiBrigham and Women's Hospital
Ranjit S BindraYale School of Medicine
Joseph F CostelloUniversity of California-San Francisco
Craig HorbinskiFeinberg School of Medicine, Northwestern University
Craig HorbinskiNorthwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Craig HorbinskiFeinberg School of Medicine, Northwestern University
Raymond Y HuangHarvard Medical School
Raymond Y HuangBrigham and Women's Hospital
Keith L LigonHarvard Medical School
Keith L LigonBrigham and Women's Hospital
David SchiffUniversity of Virginia Health System
Andreas von DeimlingUniversity Hospital Heidelberg, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Patrick Y WenHarvard Medical School
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
Patrick Y WenBrigham and Women's Hospital
  • 1 - 23

Datasets

Release 1.2